

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-0043US1	Application No. 10/561,071
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Brian Smith, et al.	
		Filing Date May 26, 2006	Group Art Unit 1624
(37 CFR §1.98(b))			

## U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/B.C./	1	4477378	Oct. 16, 1984	Gold et al.			
/B.C./	2	4584293	Apr. 22, 1986	Reiffen et al			
/B.C./	3	4737495	Apr. 12, 1988	Bomhard et al			
/B.C./	4	4957914	Sep. 18, 1990	Clark et al.			
/B.C./	5	5247080	Sep. 21, 1993	Berger et al.			
/B.C./	6	20030225057	Dec. 4, 2003	Smith et al.			
/B.C./	7	20050020573	Jan. 27, 2005	Smith et al.			
/B.C./	8	7105523	Sep. 12, 2006	Stasch et al.			
/B.C./	9	7157466	Jan. 1, 2007	McClure et al.			
/B.C./	10	7173037	Feb. 6, 2007	Alonso-Alija et al			
/B.C./	11	20070060568	Mar. 15, 2007	Smith et al.			
/B.C./	12	7211591	May 1, 2007	Tajima et al.			
/B.C./	13	7229991	Jun. 12, 2007	Merla et al.			
/B.C./	14	7230024	Jun. 12, 2007	Carpino et al			
/B.C./	15	7232823	Jun. 19, 2007	Carpino et al.			
/B.C./	16	20070275949	Nov. 29, 2007	Smith et al.			
/B.C./	17	20080009478	Jan. 16, 2008	Smith et al.			
/B.C./	18	2008/0045502	Feb. 21, 2008	Burbaum, B.W et al.			

## Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Sub-class	Translation	
							Yes	No
/B.C./	19	GB 1196229	Jun. 24, 1970	Great Britain				
/B.C./	20	CH500194	Jan. 29, 1971	Switzerland			X	
** /B.C./	21	DE 1914456	Jun. 16, 1971	Germany			X	
/B.C./	22	GB 1247306	Sep. 22, 1971	Great Britain			GB1196229	
/B.C./	23	AU 515236	Mar. 26, 1981	Australia				
/B.C./	24	GB 2133401	Jul. 25, 1984	Great Britain				

\*\* structures only

Examiner Signature /Brenda Coleman/	Date Considered 05/14/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-0043US1	Application No. 10/561,071
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Brian Smith, et al.	
		Filing Date May 26, 2006	Group Art Unit 1624
(37 CFR §1.98(b))			

### Foreign Patent Documents or Published Foreign Patent Applications

	Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Sub-class	Translation	
								Yes	No
**	/B.C./	25	DE 3418270	Nov. 21, 1985	Germany			X US4584293	
**	/B.C./	26	SU1238732	Jun. 15, 1986	Soviet Union			X Abstract	
**	/B.C./	27	EP 0204349	Dec. 10, 1986	Europe				
	/B.C./	28	EP0331130 A1	Sep. 6, 1989	Europe				
	/B.C./	29	EP0331130 B1	Sep. 6, 1989	Europe				
	/B.C./	30	WO199303015	Feb. 18, 1993	WIPO				
	/B.C./	31	EP 0285919 A1	Oct. 12, 1994	Europe				
	/B.C./	32	EP 0285919 B1	Oct. 12, 1994	Europe				
	/B.C./	33	WO2003062205	Jul. 31, 2003	WIPO				
	/B.C./	34	WO2005003096	Jan. 13, 2005	WIPO				
	/B.C./	35	WO2007/120517	Oct. 25, 2007	WIPO				

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/B.C./	36	Baindur, et al., "(±)-3-allyl-7-halo-8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines as Selective High Affinity D1 Dopamine Receptor Antagonists: Synthesis and Structure-Activity Relationship", <i>J. Med. Chem.</i> , 35:67-72 (1992)
/B.C./	37	Bickerdike, M. J., "5-HT <sub>2C</sub> Receptor Agonists as Potential Drugs for the Treatment of Obesity" <i>Current Topics in Medicinal Chemistry</i> , Vol. 3:pages 885-897 (2003)
/B.C./	38	Bos et al., "Novel Agonists of 5HT <sub>2C</sub> Receptors. Synthesis and Biological Evaluation of Substituted 2-(Indol-1-yl)-1-methylethylamines and 2-(Indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved Therapeutics for Obsessive Compulsive Disorder, <i>Journal of Medicinal Chemistry</i> (1997), 40(17), 2762-2769
/B.C./	39	Bosch, et al., "Studies on the Synthesis of Pentacyclic Strychnos Indole Alkaloids. Photocyclization of <i>N</i> -chloroacetyl-1,2,3,4,5,6-hexahydro- 1,5-methanoazocino [4,3- <i>b</i> ] Indole Derivatives", <i>Tetrahedron</i> , 41(12):2557-66 (1985)
/B.C./	40	Brenner, "Seven Membered Rings", Institute for Biomolecular Science, Dept. of Chemistry, University of Wollongong; "Progress in Heterocyclic Chemistry 13", Pergamon Press, Ch. 7:340-77 (2001)
/B.C./	41	Chumpradit, et al., "(±)-7-chloro-8-hydroxyl-1-(4-[ <sup>25</sup> I]iodophenyl)-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine: A Potential CNS D-1 Dopamine Receptor Imaging Agent", <i>J. Med. Chem.</i> , 32:1431-5 (1989)
/B.C./	42	Clark, et al., "1,9-alkano-bridged 2,3,4,5-tetrahydro-1H-3-benzazepines with Affinity for the α <sub>2</sub> -Adrenoceptor and the 5-HT <sub>1A</sub> Receptor", <i>J. Med. Chem.</i> , 33:633-41 (1990)

\*\* structures only

Examiner Signature  /Brenda Coleman/	Date Considered  05/14/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-0043US1	Application No. 10/561,071
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Brian Smith, et al.	
		Filing Date May 26, 2006	Group Art Unit 1624

(37 CFR §1.98(b))

## Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/B.C./	43	Clinical trial NCT00768612, "Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia Study", 2008 <a href="http://clinicaltrials.gov/ct2/show/record/NCT00768612">http://clinicaltrials.gov/ct2/show/record/NCT00768612</a>
/B.C./	44	DeMarinis et al., "Development of an Affinity Ligand for Purification of $\alpha_2$ -Adrenoceptors from Human Platelet Membranes", <i>J. Med. Chem.</i> , 27, 918-921 (1984)
/B.C./	45	Di Giovanni et al., "Serotonin/dopamine interaction - Focus on 5-HT <sub>2C</sub> receptor, a new target of psychotropic drugs" <i>Indian Journal of Experimental Biology</i> , Vol. 40:pages 1344-1352 (2002)
/B.C./	46	Dhonnchadh, et al., "Anxiolytic-like Effects of 5-HT <sub>2C</sub> Ligands on Three Mouse Models of Anxiety", <i>Behavioral Brain Research</i> , 140:203-214 (2003)
/B.C./	47	Dixit et al., "gents Acting on Central Nervous System: Part XXIII-2-Substituted 1, 2, 3, 4, 6, 7, 12, 12a-Octahydropyrazino[2,1-b][3] benzazepines & 3-Substituted 1, 2, 3, 4, 4a, 5, 6, 11-Octahydropyrazino[1,2-b][2] benzazepines", <i>CDRI Communication No. 1969, 893-97 (1974)</i>
/B.C./	48	Draper, et al., "Novel Stereoselective Syntheses of the Fused Benzazepine Dopamine D <sub>1</sub> Antagonist (6aS, 13bR)-11-chloro-6, 6a,7,8,9, 13b-hexahydro-7-methyl-5H-benzo[d]naphth[2, 1-b]azepin-12-ol (Sch 39166): 1. Aziridinium Salt Based Syntheses", <i>Organic Process Research &amp; Development</i> , 2(3):175-85 (1998)
/B.C./	49	Draper, et al., "Novel Stereoselective Syntheses of the Fused Benzazepine Dopamine D <sub>1</sub> Antagonist (6aS, 13bR)-11-chloro-6, 6a,7,8,9, 13b-hexahydro-7-methyl-5H-benzo[d]naphth[2, 1-b]azepin-12-ol (Sch 39166): 2. L-Homophenylalanine-Based Syntheses", <i>Organic Process Research &amp; Development</i> , 2(3):186-93 (1998)
/B.C./	50	Garrison, "Defining obesity: An adventure in cardiovascular disease epidemiology", <i>Journal of Nutritional Biochemistry</i> (1998), 9(9), 493-500
/B.C./	51	Gerritz, et al., "Two General Routes to 1,4-disubstituted-2,3,4,5-tetrahydro-1H-3-benzazepines", <i>Organic Letters</i> , 2(25):4099-102 (2000)
/B.C./	52	Guillory, "Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids", in <i>Polymorphism in Pharmaceutical Solids</i> , ed. Harry G. Brittain, vol. 95, chapter 5, Marcel Dekker, Inc., New York 1999, pages 183-226
/B.C./	53	Green and Wuts, et al., "Protective Groups in Organic Synthesis", 3 <sup>rd</sup> Ed., Wiley and Sons (1999)*
/B.C./	54	Halford, et al., "o-phenylenediacetamide and Other Compounds Related to 3,1H-benzazepine", <i>J. Org. Chem.</i> 17:1646-52 (1952)
/B.C./	55	Hasan, et al., "Syntheses of N-chloroacyl- $\beta$ -phenylethylamine Derivatives", <i>Indian J. Chem.</i> , 9:1022-4 (1971)
/B.C./	56	Heys, et al., "A New Entry into C7-Oxygenated Tetrahydro-1H-3-benzazepines: Efficient Labeling with Carbon-14 in the Benzo Ring", <i>J. Org. Chem.</i> , 54(19):4702-6 (1989)
/B.C./	57	Isaac, "The 5-HT <sub>2C</sub> receptor as a potential therapeutic target for the design of antiobesity and antiepileptic drugs" <i>Drugs of the Future</i> (2001), 26(4), 383-393
/B.C./	58	Kaiser, et al., "6-(phenylthio)-substituted 2,3,4,5-tetrahydro-1H-3-benzazepines, a Novel Class of Dopamine Receptor Antagonists and Neuroleptics", <i>J. Med. Chem.</i> , 23(9):975-6 (1980)
/B.C./	59	Klohr, et al., "An Intramolecular Photocyclization to Form the Azepino[3,4,5-cd]Indole System", <i>Synthetic Communications</i> 18(7):671-4 (1988)
/B.C./	60	Klein, "Outcome Success in Obesity", <i>Obesity Research</i> , (2001), 9(suppl. 4):354S-358S

Examiner Signature /Brenda Coleman/	Date Considered 05/14/2009
--	-------------------------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-0043US1	Application No. 10/561,071
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Brian Smith, et al.	
		Filing Date May 26, 2006	Group Art Unit 1624
(37 CFR §1.98(b))			

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
/B.C./	61	Kienburg, et al., "Development of a Pilot Scale Process for the Anti-Alzheimer Drug (—)-Galanthamine Using Large-Scale Phenolic Oxidative Coupling and Crystallisation-Induced Chiral Conversion", <i>Organic Process Research &amp; Development</i> , 3(6):425-31 (1999)
/B.C./	62	Lacivita et al., "Selective Agents for Serotonin <sub>2C</sub> (5-HT <sub>2C</sub> ) Receptor" <i>Current Topics in Medicinal Chemistry</i> , Vol. 6:pages 1927-1970 (2006)
/B.C./	63	Lin, et al., "Benzindene Prostaglandins. Synthesis of Optically Pure 15-Deoxy-U-68,215 and its Enantiomer via a Modified Intramolecular Wadsworth-Emmons-Wittig Reaction", <i>J. Org. Chem.</i> , 52(25):5594-601 (1987)
/B.C./	64	Martin et al., "5-HT <sub>2C</sub> receptor agonists pharmacological characteristics and therapeutic potential", <i>Journal of Pharmacology and Experimental Therapeutics</i> (1998), 286(2), 913-924
/B.C./	65	Millan, et al., "5HT <sub>2C</sub> Receptors Mediate Penile Erections in Rats: Actions of Novel and Selective Agonists and Antagonists", <i>Eur. J. Pharmacol.</i> 325:9-12 (1997)
/B.C./	66	Nagle, et al., "Efficient Synthesis of $\beta$ -amino Bromides", <i>Tetrahedron Letters</i> , 41:3011-4 (2000)
/B.C./	67	Nair, et al., "Preparation of 2,3,4,5-tetrahydro-3,1H-benzazepine-2-one", <i>Indian J. Chem.</i> , 5:169-70 (1967)
/B.C./	68	Neumeyer, et al., "Development of a High Affinity and Stereoselective Photoaffinity Label for the D-1 Dopamine Receptor: Synthesis and Resolution of 7- <sup>[125I]</sup> Iodo-8-hydroxy-3-methyl-1-(4'-azidophenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine", <i>J. Med. Chem.</i> , 33(2):521-6 (1990)
/B.C./	69	Okuno, et al., "Photocyclization of N-chloroacetyl-2,5-dimethoxyphenethylamine Synthesis of Pyrrolindoles", <i>Chem. Pharm. Bull.</i> , 23(11):2584-90 (1975)
/B.C./	70	Orto, et al., "Synthetic studies of heterocyclic compounds I. Alkylation and acylation of 1,2,4,5-tetrahydro-3-methyl-3H-3-benzazepin-2-one," <i>CASREACT</i> , 1979, 93:7990 (Chemical Abstract (Online) Accession No. 1980:407990)
/B.C./	71	Pecherer, et al., "A Novel Synthesis of Aromatic Methoxy and Methyleneedioxy Substituted 2,3,4,5-tetrahydro-1H-3-benzazepines", <i>J. Het. Chem.</i> , 9:609-16 (1972)
/B.C./	72	Pfeiffer, et al., "Dopaminergic Activity of Substituted 6-chloro-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines", <i>J. Med. Chem.</i> , 25(4):352-8 (1982)
/B.C./	73	"Remington's Pharmaceutical Sciences" 17 <sup>th</sup> ed., Mack Publishing Company, Easton Pa.: 1418 (1985)
/B.C./	74	Rosenzweig-Lipson, et al., "Vabicaserin: effects of a novel 5HT <sub>2C</sub> agonist on medial prefrontal cortex neurotransmission, cognition and sensorimotor gating", <i>20th ECNP Congress</i> , Vienna, Austria (2007)
/B.C./	75	Tecott, et al., "Eating Disorder and Epilepsy in Mice Lacking 5-HT <sub>2C</sub> Serotonin Receptors", <i>Nature</i> , 374:542-546 (1996)
/B.C./	76	Vanderlaan, et al., "Synthesis and Oxidative Coupling of ( $\pm$ )-3-oxoreticoline", <i>J. Org. Chem.</i> , 50(6):743-7 (1985)
/B.C./	77	Van Oekelen et al., "5-HT <sub>2A</sub> and 5-HT <sub>2C</sub> receptors and their atypical regulation properties" <i>Life Sciences</i> , Vol. 72:pages 2429-2449 (2003)
/B.C./	78	Weinstock, et al., "Separation of Potent Central and Renal Dopamine Agonist Activity in Substituted 6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepines", <i>J. Med. Chem.</i> , 23(9):973-5 (1980)
/B.C./	79	Winkler, "Obesity and hemostasis", <i>Archives of Gynecology and Obstetrics</i> (1997), 261(1), 25-29

Examiner Signature /Brenda Coleman/	Date Considered 05/14/2009
EXAMINER: initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-0043US1	Application No. 10/561,071
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Brian Smith, et al.	
		Filing Date May 26, 2006	Group Art Unit 1624
(37 CFR §1.98(b))			

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
/B.C./	80	Wu, et al., "Amino Diol Based Asymmetric Syntheses of a Fused Benzazepine as a Selective D1 Dopamine Receptor", Organic Process Research & Development, 1(5):359-64 (1997)
/B.C./	81	Yasuda, et al., "A Novel and Stereoselective Synthesis of (±)-cephalotaxine and its Analogue", Tetrahedron Letters, 27(18):2023-6 (1986)
/B.C./	82	Yonemitsu, et al., "Photocyclization of Pharmacodynamic Amines. IV. Novel Heterocycles from N-chloroacetyl-3,4-dimethoxyphenethylamine", Journal of the American Chemical Society, 92(19):5686-90 (1970)
/B.C./	83	Yonemitsu, et al., "Photolysis of N-chloroacetyl-O-methyl-L-tyrosine to an Azaazulene", Journal of the American Chemical Society, 89(4):1039-40 (1967)
/B.C./	84	Yonemitsu, et al., "Photocyclizations of Tyrosines, Tyramines, Catecholamines, and Normescaline", Journal of the American Chemical Society, 90(3):776-84 (1968)
/B.C./	85	Yonemitsu, et al., "Photocyclization of Pharmacodynamic Amines. II. X-Ray Analysis of a Noncentrosymmetric Tetracyclic Indole", Journal of the American Chemical Society, 90(23):6522-3 (1968)
/B.C./	86	International Search Report for International Application No. PCT/US03/11076 dated October 16, 2003
/B.C./	87	International Search Report for International Application No. PCT/US2004/034917 dated February 2, 2005
/B.C./	88	International Search Report for International Application No. PCT/US2004/034914 dated March 15, 2005

\*Due to the voluminous nature of the reference, a copy of the same is not being submitted herewith. A copy will be submitted upon request.

Examiner Signature /Brenda Coleman/	Date Considered 05/14/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	